Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases

Kazuho Morichika; Takeaki Tomoyose; Taeko Hanashiro; Natsuki Shimabukuro; Keita Tamaki; Iori Tedokon; Yukiko Nishi; Sawako Nakachi; Ken-nosuke Karube; Takuya Fukushima; Takeharu Katoh; Koichi Ohshima; Hiroaki Masuzaki

doi:10.2169/internalmedicine.55.5997

CASE REPORTS

Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases

Kazuho Morichika, Takeaki Tomoyose, Taeko Hanashiro, Natsuki Shimabukuro, Keita Tamaki, Iori Tedokon, Yukiko Nishi, Sawako Nakachi, Ken-nosuke Karube, Takuya Fukushima, Takeharu Katoh, Koichi Ohshima, Hiroaki Masuzaki

Author information

Kazuho Morichika
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Takeaki Tomoyose
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Taeko Hanashiro
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Natsuki Shimabukuro
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Keita Tamaki
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Iori Tedokon
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Yukiko Nishi
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Sawako Nakachi
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan
Ken-nosuke Karube
Department of Cell Biology and Pathology, Graduate School of Medicine, University of the Ryukyus, Japan
Takuya Fukushima
Laboratory of Immunohematology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Japan
Takeharu Katoh
Department of Pathology, Kurume University School of Medicine, Japan
Koichi Ohshima
Department of Pathology, Kurume University School of Medicine, Japan
Hiroaki Masuzaki
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan

Keywords: adult T cell leukemia / lymphoma (ATL), C-C chemokine receptor type 4 (CCR4), regulatory T cell (Treg), psoriasis vulgaris, autoinflammatory disease

JOURNAL OPEN ACCESS

2016 Volume 55 Issue 10 Pages 1345-1349

DOI https://doi.org/10.2169/internalmedicine.55.5997

Details

Abstract

Adult T cell leukemia / lymphoma (ATL) is one of the most aggressive hematological malignancies caused by human T-lymphotropic virus type-I (HTLV-1). Mogamulizumab is a new defucosylated humanized monoclonal antibody agent which targets C-C chemokine receptor type 4 (CCR4) expressed occasionally on the surface of ATL cells. However, adverse events such as drug eruptions have also been highlighted, at least in part, via the dysfunction of regulatory T cells (Tregs). We herein report a pronounced recurrence of systemic psoriasis vulgaris accompanied by the treatment of mogamulizumab in a patient with ATL. Pathological examinations may suggest a mechanistic link between the recurrence of autoinflammatory diseases and anti-CCR4 antibody therapies.

Corresponding author

Register with J-STAGE for free!